This patent teaches how to generate a myocardial graft using embryonic stem cells that have been induced to differentiate into the cardiac lineage. This patent is especially useful for post myocardial infarction in which scar tissue replaces functional myocardium resulting in decreased cardiac output. Numerous methods have been previously described for generation of myocardial cells from...
This patent teaches that administration of "mega-dose" hematopoietic stem cell grafts may be useful for circuventing the requirement of completely ablating the recipient immune system. Use of this patent may allow for reduced neutropenic times and increased survival after bone marrow transplantation.
This patent teaches how to perform bone marrow transplantation, or transplantation of stem cells with hematopoietic potential, without completely ablating the recipient hematopoietic system. The patent uses various antibodies to not-completely deplete the host, but just enough so that the stem cells administered are not completely cleared away.
This patent teachs ways of overcoming neutropenia by administration of committed stem cells that differentiate into the neutrophil lineage. This work has the potential to be very beneficial in nuclear accidents where a quick supply of neutrophils is needed. The biggest barrier is whether allogeneic neutrophil committed stem cells may be used or whether the stem cells strictly have to be...
This patent covers ways of treating neutropenic patients through administration of stem cells that are committed to differentiating into neutrophils. This patent is useful for the treatment of patients that are suppressed in terms of white blood cell numbers.
This patent teaches how to use growth hormone, as well as other factors for the repair of articular cartilage. The method is useful for developing not only therapeutic kits, but also as a stepping stop for new methods of using stem cells, both endogenous and exogeneous in cartilage repair.
This patent covers fetally derived neuronal stem cells, alone, and after transfection with therapeutic genes. These stem cells may be transfected in order to secrete trophic factors that would allow endogenous brain stem cells to proliferate. On the other hand, they may be transfected with anti-apoptotic genes such as Xiap. Xiap transfection would allow the cells to maintain viability.
If I read this currently, this patent seems to cover the use of blood mesenchymal stem cells for stimulation of immune responses to antigens. This is the opposite to what the current knowledge of mesenchymal stem cells is...that being that they are immune suppressive. If these cells were immune stimulatory then the current Phase III trials for graft versus host...
This patent teaches how to treat diabetes by the activation of endogenous stem cells through administration of gastrin and EGF. This patent is in clinical trials.
This patent covers ways of generating neutrophil-committed stem cells. These neutrophil committed stem cells are useful for prevention of infection after myeloablation.